2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of treatments for cancer. Co. develops chimeric antigen receptor (CAR) T cell therapy for multiple myeloma. Co. is developing various clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as preclinical programs, including bbT4015, a CAR T cell therapy targeting MUC16. Additionally, Co. is developing ABECMA for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy. The TSVT stock yearly return is shown above.
The yearly return on the TSVT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TSVT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|